Tissue plasminogen activator and obstructed central venous catheters
✍ Scribed by Kleta, Robert; Schleef, Jürgen; Jürgens, Heribert
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 19 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Laminated occlusive thrombus was induced in the rat inferior vena cava (IVC) by a distal stenosis and injection of thrombin. Immunocytochemistry was performed on serial cryostat sections of the thrombus for tissue plasminogen activator (tPA) and a variety of phenotype markers for mononuclear ce
Defibrotide, a polydeoxyribonucleotide of mammalian origin, has been shown to reduce the blood level of the plasminogen activator inhibitor, and so to increase the activity of tissue plasminogen activator without any adverse effect. A randomized, double-blind, placebo-controlled study has been done
## Abstract Tissue plasminogen activator (tPA) is the only FDA‐approved treatment of thrombotic stroke and is a major parenchymal serine protease in the brain. However, it has been implicated in a plethora of brain pathologies, raising concern about its use as a safe therapeutic. tPA is thought to